Related Experiment Videos
Inhaled nitric oxide in cardiology
C S Hayward1, P S Macdonald, A M Keogh
1Heart Failure and Transplant Unit, St Vincent's Hospital, Victoria St, Darlinghurst, NSW 2010, Australia. chayward@stvincents.com.au
Expert Opinion on Investigational Drugs
|January 5, 2002
Summary
Inhaled nitric oxide (INO) rapidly dilates pulmonary arteries, proving effective for acute pulmonary hypertension in cardiac patients. This review explores INO
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Pulmonary hypertension is a critical condition in cardiac patients, impacting both medical and surgical management.
- Selective pulmonary vasodilatation is essential for improving outcomes in these patients.
- Inhaled nitric oxide (INO) offers a targeted approach to managing pulmonary hypertension.
Purpose of the Study:
- To review the established and emerging roles of inhaled nitric oxide (INO) in cardiac patient management.
- To compare INO with alternative pulmonary vasodilator strategies.
- To discuss the application of INO in various cardiac conditions, including failure, post-operative states, and congenital heart disease.
Main Methods:
- Literature review of studies on inhaled nitric oxide in cardiac patients.
- Analysis of clinical trials and case reports.
- Comparative assessment of INO efficacy and safety against alternative treatments.
Main Results:
- INO demonstrates rapid and selective pulmonary vasodilatation, beneficial in acute pulmonary hypertension.
- It is valuable for assessing pulmonary vasodilator capacity in chronic pulmonary hypertension.
- INO is effective in managing reversible pulmonary hypertension in diverse cardiac populations.
Conclusions:
- Inhaled nitric oxide is a key therapeutic agent in managing pulmonary hypertension in cardiac patients.
- Ongoing research explores newer alternatives with improved administration and prolonged effects.
- INO remains a critical tool for both acute management and diagnostic assessment in cardiovascular care.